Literature DB >> 21244429

Low-n oligomers as therapeutic targets of Alzheimer's disease.

Kenjiro Ono1, Masahito Yamada.   

Abstract

The pathogenesis of Alzheimer's disease involves the progressive accumulation of amyloid β-protein (Aβ). Recent studies using synthetic Aβ peptides, a cell culture model, Aβ precursor protein transgenic mice models suggest that pre-fibrillar forms of Aβ are more deleterious than extracellular fibril forms. Recent findings obtained using synthetic Aβ peptides and human samples indicated that low-n oligomers (from dimers to octamers) may be proximate toxins for neuron and synapse. Here, we review the recent studies on the soluble oligomers, especially low-n oligomers in Alzheimer's disease.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21244429     DOI: 10.1111/j.1471-4159.2011.07187.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  26 in total

Review 1.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

2.  Stability of Aβ-fibril fragments in the presence of fatty acids.

Authors:  Wenhui Xi; Elliott K Vanderford; Qinxin Liao; Ulrich H E Hansmann
Journal:  Protein Sci       Date:  2019-09-11       Impact factor: 6.725

3.  Seeding plaques in Alzheimer's disease.

Authors:  Marco A M Prado; Gerald Baron
Journal:  J Neurochem       Date:  2012-03       Impact factor: 5.372

4.  Phenolic compounds prevent amyloid β-protein oligomerization and synaptic dysfunction by site-specific binding.

Authors:  Kenjiro Ono; Lei Li; Yusaku Takamura; Yuji Yoshiike; Lijun Zhu; Fang Han; Xian Mao; Tokuhei Ikeda; Jun-ichi Takasaki; Hisao Nishijo; Akihiko Takashima; David B Teplow; Michael G Zagorski; Masahito Yamada
Journal:  J Biol Chem       Date:  2012-03-05       Impact factor: 5.157

Review 5.  Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?

Authors:  Jacques Fantini; Henri Chahinian; Nouara Yahi
Journal:  Protein Sci       Date:  2020-07-13       Impact factor: 6.725

Review 6.  The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease.

Authors:  Yash B Joshi; Phillip F Giannopoulos; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2015-02-20       Impact factor: 14.819

7.  The role of wild-type tau in Alzheimer's disease and related tauopathies.

Authors:  Chih Hung Lo; Jonathan N Sachs
Journal:  J Life Sci (Westlake Village)       Date:  2020-12

8.  Synthesis of tetrahydroxybiphenyls and tetrahydroxyterphenyls and their evaluation as amyloid-β aggregation inhibitors.

Authors:  Craig B Stevens; James M Hanna; Robin K Lammi
Journal:  Bioorg Med Chem Lett       Date:  2013-02-04       Impact factor: 2.823

9.  Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated β-Amyloid and Inhibits the Formation of Neurotoxic Oligomers.

Authors:  Renae K Barr; Giuseppe Verdile; Linda K Wijaya; Michael Morici; Kevin Taddei; Veer B Gupta; Steve Pedrini; Liang Jin; Joseph A Nicolazzo; Erin Knock; Paul E Fraser; Ralph N Martins
Journal:  J Biol Chem       Date:  2015-11-04       Impact factor: 5.157

Review 10.  The 5-Lipoxygenase as modulator of Alzheimer's γ-secretase and therapeutic target.

Authors:  Jin Chu; Domenico Praticò
Journal:  Brain Res Bull       Date:  2016-03-19       Impact factor: 4.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.